Journal Home
Search for

Volume 90, Issue 5, Pages 2016.e7-2016.e10 (November 2008)


View previous. 141 of 155 View next.

Pregnancy in a hermaphrodite with a male-predominant mosaic karyotype

Samantha A. Schoenhaus, D.O., Scott E. Lentz, M.D., Peter Saber, D.O., Malcom G. Munro, M.D., Seth Kivnick, M.D.Corresponding Author Informationemail address

Received 5 January 2008; received in revised form 25 January 2008; accepted 31 January 2008. published online 04 April 2008.

Objective

To report a pregnancy in a hermaphrodite and review of the literature.

Design

Case report and literature review.

Setting

Clinical.

Patient(s)

A patient with male-predominant mosaic karyotype 96% 46XY.

Intervention(s)

Removal of left ovotestis in combination with a supracervical hysterectomy and bilateral salpingo-oophorectomy.

Main Outcome Measure(s)

Identification of published cases of pregnancy and hermaphroditism.

Result(s)

The current patient had previous pregnancy and a wedge biopsy of her left gonad, which demonstrated an ovotestis and an area suspicious for a gonadoblastoma. After delivery of her second pregnancy, the patient underwent a hysterectomy and bilateral salpingo-oophorectomy. The histopathologic evaluation following bilateral oophorectomy demonstrated a residual ovotestis without further evidence of a gonadoblastoma. Review of the literature identified 10 other cases of pregnancy in a hermaphrodite patient.

Conclusion(s)

This is the 11th reported case of fertility in a true hermaphrodite and only the second report of a mosaic true hermaphrodite to demonstrate fertility. This is the only case of a pregnancy involving a male-predominant mosaic 96% 46XY and the only case to confirm the genetics of the offspring.

Kaiser Permanente Southern California, West Los Angeles and Los Angeles Medical Centers, Los Angeles, California

Corresponding Author InformationReprint requests: Seth Kivnick, M.D., Kaiser Permanente, 6041 Cadillac Blvd., Los Angeles, CA 90034 (FAX: 323-857-3946).

 S.A.S. has nothing to disclose. S.E.L. has nothing to disclose. P.S. has nothing to disclose. M.G.M. is a consultant for Ethicon Women's Health, Covidien, Gynesonics, Karl Storz Endoscopy, and AMAG Pharmaceuticals and is a shareholder in Gynesonics and Impres Medical. S.K. has nothing to disclose.

PII: S0015-0282(08)00233-1

doi:10.1016/j.fertnstert.2008.01.104


View previous. 141 of 155 View next.